Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations

Journal of Infectious Diseases

Volumn 182, Issue 2, 2000, Pages 517-525

  Zhou, J ^a   Dong, Y ^a   Zhao, X ^a   Lee, S ^e   Amin, A ^b   Ramaswamy, S ^b,c   Domagala, J ^d   Musser, J M ^b,c   Drlica, K ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d PFIZER INC   (United States)

^e WM Keck Structural Biology Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 (4 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIBIOTIC AGENT; CIPROFLOXACIN; ENROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; GENE MUTATION; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; SELECTION (GENETICS); STRUCTURE-ACTIVITY RELATIONSHIP; VARIATION (GENETICS);

EID: 0033836223     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315708     Document Type: Article

References (37)

1. The emergence of drug-resistant tuberculosis in New York City
2. Trends in the susceptibility of tuberculosis in New York City, 1987-1991: New York City area tuberculosis working group
3. Origin and interstate spread of a New York City multidrug resistant Mycobacterium tuberculosis clone family: Adverse implications for tuberculosis control in the 21st century
4. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug resistant Mycobacterium tuberculosis
5. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons
6. Tuberculosis in prisons
7. Multidrug resistance: A sigu of the times
8. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
9. DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance
10. Fluoroquinolone action against mycobacteria: Effects of C8 substituents on bacterial growth, survival, and resistance
11. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
12. Gatifloxacin activity against quinolone-resistant gyrase: Allele-specific enhancement of bacteriostatic and bactericidal activity by the C-8-methoxy group
13. Emergence of fluoroquinolone-resistant tuberculosis in New York City
14. Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes, and characterization of quinolone resistance mutations
15. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with H1V-related tuberculosis and characterization of a strain with levofloxacin monoresistance
16. Strategies to minimize the development of antibiotic resistance
17. DNA gyrase, topoisomerase IV, and the 4-quinolones
18. Mechanisms of quinolone resistance
19. Induction of the SOS response by new 4-quinolones
20. Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents
21. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
22. Genetic systems in mycobacteria
23. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination
24. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis
25. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis Complex strains: Evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis
26. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C8-methoxyl group on survival in liquid media and in human macrophages
27. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
28. In vitro selective antibiotic concentrations of β-lactams for penicillin-resistant Streptococcus pneumoniae populations
29. Emergence of multidrug-resistant tuberculosis in a community-based directly observed treatment programme in rural South Africa
30. Impact of gyr A and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli
31. Bacterial mutagenicity and the 4-quinolones
32. Induction of the SOS response in Escherichia coli by 4-quinolone antimicrobial agents
33. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
34. Analysis of gyr A and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
35. Crystal structure of the breakage-reunion domain of DNA gyrase
36. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid
37. A general strategy for restricting the selection of antibiotic-resistant mutants derived from fluoroquinolone studies